Scrip Asia 100 - GSK takes the flexible approach to Asian growth
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's approach to growing its business across the Asia-Pacific region recognises the need for distinct strategies tailored to each national market. This may involve a blend of price cuts, regional co-promotion partnerships and targeted M&A deals. The company also realises that innovation can come from any source, Marc Dunoyer tells Ian Haydock in an exclusive one-on-one interview.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.